COST-UTILITY ANALYSIS OF DELAYED-RELEASE DIMETHYL FUMERATE FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN PORTUGAL

被引：2
|
作者：
Silva Miguel, L. [1 ]
de Sa, J. [2 ]
Pinheiro, B. [1 ]
Acosta, C. [3 ]
机构：
[1] CISEP Res Ctr Portuguese Econ, Lisbon, Portugal
[2] Ctr Hosp Lisboa, Lisbon, Portugal
[3] Biogen Idec Inc, Lisbon, Portugal
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.2471
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND56
引用
收藏
页码：A758 / A758
页数：1
相关论文
共 50 条
  • [31] Absolute Lymphocyte Count in Patients with Relapsing-Remitting Multiple Sclerosis Treated with Delayed-release Dimethyl Fumarate: Considerations for Patient Management
    Fox, Robert
    Chan, Andrew
    Gold, Ralf
    Phillips, J. Theodore
    Yang, Lili
    Liu, Shifang
    Prada, Claudia
    Ray, Soma
    Mehta, Devangi
    Taylor, Catherine
    Fay, Monica
    NEUROLOGY, 2017, 88
  • [32] COST-EFFECTIVENESS ANALYSIS OF DIMETHYL FUMARATE IN THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY
    Mantovani, L. G.
    Furneri, G.
    Cortesi, P. A.
    Puma, E.
    Santoni, L.
    Prosperini, L.
    VALUE IN HEALTH, 2019, 22 : S740 - S741
  • [33] Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: an overview
    Bomprezzi, Roberto
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2015, 8 (01) : 20 - 30
  • [34] COMPARATIVE EFFECTIVENESS USING A MATCHING-ADJUSTED INDIRECT COMPARISON BETWEEN DELAYED-RELEASE DIMETHYL FUMARATE AND FINGOLIMOD FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Fox, R. J.
    Cutter, G.
    Chan, A.
    Xiao, J.
    Okwuokenye, M.
    Levison, D.
    Lewin, J.
    Edwards, M. R.
    Marantz, J. L.
    VALUE IN HEALTH, 2015, 18 (07) : A750 - A750
  • [35] Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of relapsing-remitting multiple sclerosis
    Fox, R. J.
    Cutter, G.
    Chan, A.
    Xiao, J.
    Okwuokenye, M.
    Levison, D.
    Lewin, J. B.
    Edwards, M. R.
    Marantz, J. L.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 530 - 531
  • [36] Delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis - findings from a real-world setting in Russian Federation
    Davydovskaya, M.
    Pozhidaeva, N.
    Dubchenko, E.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 934 - 935
  • [37] Delayed-release Dimethyl Fumarate Demonstrates Sustained Efficacy over Nine Years in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis
    Gold, Ralf
    Giovannoni, Gavin
    Phillips, J. Theodore
    Bar-Or, Amit
    Fox, Robert J.
    Chen, Chongshu
    Miller, Catherine
    NEUROLOGY, 2019, 92 (15)
  • [38] Delayed-release dimethyl fumarate demonstrates sustained efficacy over nine years in newly diagnosed patients with relapsing-remitting multiple sclerosis
    Gold, R.
    Giovannoni, G.
    Phillips, J. T.
    Bar-Or, A.
    Fox, R. J.
    Chen, C.
    Miller, C.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 498 - 499
  • [39] Safety of Delayed-release Dimethyl Fumarate in Relapsing-Remitting Multiple Sclerosis Patients from ENDORSE: Seven-Year Interim Results
    Pozzilli, Carlo
    Phillips, J. Theodore
    Fox, Robert J.
    Prada, Claudia
    Yang, Lili
    Taylor, Catherine
    Fay, Monica
    NEUROLOGY, 2017, 88
  • [40] MRI Outcomes at Seven Years in Relapsing-Remitting Multiple Sclerosis Patients Treated With Delayed-release Dimethyl Fumarate in DEFINE, CONFIRM, and ENDORSE
    Arnold, Douglas L.
    Fox, Robert J.
    Gold, Ralf
    Havrdova, Eva
    Kappos, Ludwig
    Yousry, Tarek
    MacManus, David
    Yang, Lili
    Riester, Katherine
    Taylor, Catherine
    Fay, Monica
    NEUROLOGY, 2017, 88
12345